Investment Banking

New Federal Funding, Electric Vehicle Growth Put the Highway Safety Services Industry in Strong Position

America’s roads and highways—in disrepair for years—are set for major improvements after an infusion of federal money and upgrades necessitated by the growing popularity of electric vehicles. That’s good news for companies that provide road and highway safety services, and for investors eyeing opportunities in what is a massive and highly fragmented market.

Key Takeaways

  • The state of the U.S. highway system and the impact of new federal funding
  • The growing popularity of electric vehicles and their effect on road improvements
  • How a focus on safety is increasing due in part to autonomous vehicles
  • What is needed to successfully navigate the local highway safety services landscape
  • Major industry participants, M&A activity, and critical investor focus areas

This is the first entry in William Blair’s series “Investing in Infrastructure Services.” If you’d like to learn more and access detailed research on market participants, accelerating investment activity in the space, and important considerations for potential investors, please contact our team or complete the form below.

Contact Us

Andy Jessen, Managing Director Co-Head of M&A
Eric Bukovac, Vice President

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

On Holding AG: Initiation of Research Coverage

William Blair initiated research coverage of On Holding AG (ONON $32.87), a fast-growing performance and lifestyle brand based in Switzerland selling athletic footwear, primarily in running, but with a growing presence in newer categories and apparel.

Read more

Cullinan Oncology, Inc.: Initiation of Research Coverage

William Blair initiated research coverage of Cullinan Oncology, Inc. (CGEM $17.37), a company focused on advancing modality-agnostic targeted therapies for cancer, with a broad pipeline encompassing small molecules and multifunctional therapies across a diverse range of oncologic targets.

Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures